Peak Pharma Commercial Partners, a New York City-based investment fund dedicated to the acquisition and growth of branded, generic and over-the-counter pharmaceutical products, has announced the creation of Resilia Pharmaceuticals.
Resilia's product line includes:
- Ecoza (econazole nitrate) topical foam, 1%, an antifungal medicine indicated for the treatment of interdigital tinea pedis or athlete's foot
- Recedo topical gel, a prescription product for scar management
- Neosalus foam, a nonsteroidal, nonceramide product for treating a variety of dermatoses including atopic dermatitis and allergic dermatitis
- Neocera the ceramide version of Neosalus
All of these products are currently approved and marketed in the U.S.
"These four branded dermatology products represent a strong platform from which to build a new pharma company dedicated to promoting outstanding patient outcomes," said Harsha Murthy, executive chairman of Resilia Pharmaceuticals' board of directors. "We at Resilia bring our industry experience to the important business of promoting health. Our motto is 'Restore, Rebuild, Revive.' We wish to keep good products on the market at reasonable prices that deliver great value to patients and drive strong returns for our investors."
